Asacol and Skin atrophy - a phase IV clinical study of FDA data

Summary:

Skin atrophy is reported as a side effect among people who take Asacol (mesalamine), especially for people who are female, 60+ old, also take Enstilar, and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people have Skin atrophy when taking Asacol. It is created by eHealthMe based on reports of 19,898 people who have side effects when taking Asacol from the FDA, and is updated regularly.

What is Asacol?

Asacol has active ingredients of mesalamine. It is often used in ulcerative colitis. eHealthMe is studying from 20,618 Asacol users. Check the latest studies of Asacol.

What is Skin atrophy?

Skin atrophy (wasting of skin) is found to be associated with 624 drugs and 716 conditions by eHealthMe. Check the latest studies of Skin atrophy.

On Aug, 01, 2026

19,898 people reported to have side effects when taking Asacol.
Among them, 17 people (0.09%) have Skin atrophy.

Among these 17 people:

What is the gender of people who have Skin atrophy when taking Asacol? *

female: 62.5 %
male: 37.5 %

What is the age of people who have Skin atrophy when taking Asacol? *

What are other drugs people take besides Asacol? *

What are other side effects people have besides Skin atrophy? *

Pain: 14 people, 82.35%
Dry Skin: 10 people, 58.82%
Drug Ineffective: 10 people, 58.82%
Gait Disturbance: 9 people, 52.94%
Productive Cough: 8 people, 47.06%
Limb Discomfort (discomfort in leg): 8 people, 47.06%
Musculoskeletal Discomfort (discomfort in the body's muscles, joints, tendons, ligaments and nerves): 8 people, 47.06%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 8 people, 47.06%
Chills (felling of cold): 8 people, 47.06%
Diarrhea: 8 people, 47.06%

What are the existing conditions these people have? *

Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 8 people, 47.06%
Thrombosis (formation of a blood clot inside a blood vessel): 2 people, 11.76%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 11.76%
High Blood Pressure: 2 people, 11.76%
Fluid Retention (an abnormal accumulation of fluid in the blood): 2 people, 11.76%
Cardiac Disorder: 2 people, 11.76%
Arrhythmias (irregular heartbeat): 2 people, 11.76%
Stress And Anxiety: 1 person, 5.88%
Pain: 1 person, 5.88%
High Blood Cholesterol: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Asacol and have Skin atrophy?

- Check whether Skin atrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Asacol:

Asacol (20,618 reports)

Skin atrophy treatments and more:

Skin atrophy (6,670 reports)

Browse all side effects of Asacol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin atrophy:

Skin atrophy (624 drugs)

Browse all the conditions that are associated with Skin atrophy:

Skin atrophy (716 conditions)

Related publications that referenced our studies

Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .
Jacobsson H, Eriksen J, Karlén P, "Mesalazine-induced renal calculi", The American journal of case reports, 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on mesalamine (the active ingredients of Asacol) and Asacol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.